|
AU2013205446A1
|
|
Bicyclic amides for enhancing glutamatergic synaptic responses
|
|
AU2010208646A1
|
|
Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
|
|
EP2195303A2
|
|
3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
|
|
CN101862330A
|
|
Bicyclic amide is used for the treatment of application in the medicament of respiration inhibition in preparation
|
|
MX2009012430A
|
|
Di-substituted amides for enhancing glutamatergic synaptic responses.
|
|
UA93306C2
|
|
3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
|
|
CN101626686A
|
|
Be used to improve the 3-substituting group-1,2 of glutamatergic synaptic responses, 3-phentriazine ketone compounds
|
|
AU2005208871A1
|
|
Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
|
|
EP1592464A2
|
|
Method of treating cognitive decline due to sleep deprivation and stress
|
|
GEP20063859B
|
|
Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
|
|
AU5279502A
|
|
Treatment of schizophrenia with ampakines and neuroleptics
|
|
AU2378299A
|
|
Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
|
|
CA2306817A1
|
|
Treatment of schizophrenia with ampakines and neuroleptics
|
|
US5985871A
|
|
Benzoxazine compounds for enhancing synaptic response
|
|
US5650409A
|
|
Benzoyl piperidines/pyrrolidines for enhancing synaptic response
|
|
AU7050694A
|
|
Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
|
|
AU6836394A
|
|
Use of metabotropic receptor agonists in progressive neurodegenerative deseases
|
|
AU4544993A
|
|
Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
|
|
WO9211850A2
|
|
Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
|
